Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Grace Therapeutics, Inc

GRCE ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$2.14

▼ -4.04%

Market Cap $45.02M · Vol 24.69K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$45.02M

Micro Cap

Div Yield

N/A

EPS Growth

-43.62%

YoY

RSI (14)

49.15

Momentum

Beta

0.31

vs Market

52W High

$5.16

58.53% below

52W Low

$1.79

19.55% above

Volume

24.69K

Avg 41.48K

P/B

1.16

Price-to-book

ROE

N/A

Return on equity

Free Float

81.32%

Public shares

Shariah Compliance8 STANDARDS

✗ Grace Therapeutics, Inc (GRCE) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does GRCE pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

-0.93%

-3.60%

-51.58%

YTD

-38.68%

-30.97%

+7.54%

-83.56%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-7,793,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-13.69% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.16
P/FCF	N/A
EPS Growth	-43.62%
Outstanding Shares	21.04M

Technical Indicators

50-Day SMA	$2.22
200-Day SMA	$3.04
RSI (14)	49.15
Beta	0.31
52-Week High	$5.16
52-Week Low	$1.79

Volume Today	24.69K
Avg Daily Volume (30D)	41.48K
Relative Volume	0.60x
Volatility (10D)	43.35
Volatility (30D)	34.49
Free Float	81.32%

Analyst Consensus

BUY

Current Price $2.14

Mean Target $6.00

52W Low$1.79 52W High$5.16

Current

Target

$1.79 $5.16

Current Analyst target

+180.37% upside potential · 2 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001SFYCM5

ISINUS00439U1043

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 13, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +0.57% ARGX.BR argenx SE -1.19% ARGX argenx SE +0.50% INSM Insmed Incorporated +2.22% 2269.HK WuXi Biologics (Cayman) Inc. +1.46%

Company Profile

Grace Therapeutics, Inc. is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, and reduced side effects. Its lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. The nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. Its other pipeline includes GTX-102, which is targeted as the first potential therapy for the treatment of ataxia-telangiectasia (AT) in a pediatric population and GTx-101, which is a topical administration via a bioadhesive, film-forming polymer, for the treatment of pain associated with postherpetic neuralgia.